Sotrovimab News and Research

RSS
Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

UK government signs two new deals to combat the Omicron variant

UK government signs two new deals to combat the Omicron variant

Reduced antibody-mediated neutralization by the SARS-CoV-2 Omicron variant

Reduced antibody-mediated neutralization by the SARS-CoV-2 Omicron variant

Impact of SARS-CoV-2 Omicron mutations on the use of therapeutic antibodies in COVID-19 treatment

Impact of SARS-CoV-2 Omicron mutations on the use of therapeutic antibodies in COVID-19 treatment

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

New study demonstrates SARS-CoV-2 Omicron antibody escape

New study demonstrates SARS-CoV-2 Omicron antibody escape

Monoclonal antibody activity against SARS-CoV-2 Omicron variant

Monoclonal antibody activity against SARS-CoV-2 Omicron variant

Effect of SARS-CoV-2 variant emergence on efficacy of neutralizing antibodies and vaccines

Effect of SARS-CoV-2 variant emergence on efficacy of neutralizing antibodies and vaccines

SARS-CoV-2 Delta variant mutation sites

SARS-CoV-2 Delta variant mutation sites

Study shows neutralizing capacity of monoclonal antibodies against SARS-CoV-2 variants of concern

Study shows neutralizing capacity of monoclonal antibodies against SARS-CoV-2 variants of concern

Effectiveness of sotrovimab demonstrated in patients with mild to moderate COVID-19

Effectiveness of sotrovimab demonstrated in patients with mild to moderate COVID-19